Windgap Medical raises $12m for epinephrine auto-injector

Windgap Medical has raised $12 million from 106 investors as part of a $27 million round, according to a document filed with the SEC.

The Watertown, Mass.-based company is developing an epinephrine auto-injector designed to treat severe allergic reactions.

Windgap Medical is reportedly working on a product that can withstand harsh temperatures and can be easily stored in a user’s pocket. In an interview with Allergy Eats, co-founder & CTO Brent Buchine described his company’s technology as “the next generation of epinephrine autoinjectors.”

It’s a solution that would likely be welcomed with open arms by consumers. A number of leading epinephrine auto-injector manufacturers reported shortages last year and the price of Mylan’s EpiPen has risen sharply over the last decade.

Also today, Novartis (NYSE:NVS) division Sandoz launched its Symjepi epinephrine pre-filled syringe in the U.S. as an alternative to epinephrine auto-injectors.

Sandoz described Symjepi as an “affordable” alternative to EpiPens but did not disclose the product’s price.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW